Real-world Treatment Patterns and Clinical Outcomes in Epidermal Growth Factor Receptor(EGFR)-Mutant Unresectable Locally Advanced NSCLC: A Retrospective Multi-center Study

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.

Start Date01 Mar 2020

Sponsor / Collaborator

Chinese Academy of Medical Sciences

NCT03529084

/ WithdrawnPhase 3

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

This is a phase III, open label, randomized controlled multi-center global study designed to evaluate the safety and efficacy of single agent nazartinib (EGF816) compared with investigator's choice (erlotinib or gefitinib) in patients with locally advanced or metastatic NSCLC who are treatment naïve and whose tumors harbor EGFR activating mutations (L858R or ex19del).

Start Date24 Jul 2018

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT03516214

/ CompletedPhase 1IIT

An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment

The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).

Start Date25 Apr 2018

Sponsor / Collaborator

University of Cologne Executive School GmbH

100 Clinical Results associated with Nazartinib

100 Translational Medicine associated with Nazartinib

100 Patents (Medical) associated with Nazartinib

Literatures (Medical) associated with Nazartinib

01 Sep 2025·Anti-Cancer Agents in Medicinal Chemistry

Virtual Screening and Biological Evaluation of T22306 as a Potent Third-generation EGFR Inhibitor for NSCLC Treatment

Article

Author: Li, Min ; Ruan, Wei ; Zhang, Han ; Long, Li ; Xu, Shan ; Wang, Linxiao ; Fan, Dang ; Wang, Ran

Objectives::

According to the data, mutations in EGFR-related genes are the main cause of Non-Small Cell Lung Cancer (NSCLC), necessitating the development of new drug constructs for EGFR-TKIs particularly important. This study aimed to screen potential third-generation EGFR-TKIs to address the emerging drug resistance challenges in NSCLC.

Methods::

In this study, virtual screening, molecular dynamics modeling, and bioactivity evaluation were carried out to find a potential EGFR inhibitor that could overcome the L858R/T790M mutation. At first, 12 potential compounds were screened step by step from about 250,000 structures by virtual screening. These 12 compounds were subjected to MTT antitumor activity evaluation and kinase inhibition assay to select compounds with strong antiproliferative effects on cancer cells. Then, the preferred compounds were subjected to time-dependent assay, scratch assay, AO staining assay, and hemolysis assay. Finally, the preferred compound was subjected to molecular docking and molecular dynamics simulation with 5HG7 protein.

Result::

The IC50 of T22306 on H1975 cells was 9.17 μM. In further kinase evaluation, the kinase inhibition of EGFRL858R/T790M was 69.17%. In addition, time-dependent experiments and scratch and AO staining assays confirmed the potential of T22306 as an EGFR-TKI inhibitor, while hemolysis assays demonstrated no significant toxicity. Finally, molecular docking revealed the formation of critical hydrogen bonds between T22306 and LEU-718. Furthermore, molecular dynamics simulations showed that the T22306-5HG7 complex has a low binding energy (-117.73 ± 18.69 kJ/mol), thus suggesting that T22306 binds tightly to the target protein 5HG7.

Conclusion::

In this study, we rapidly screened potential compounds against NSCLC with the help of virtual screening technology. Further in vitro experiments demonstrated that T22306 successfully overcame the L858R/T790M mutation and could be a potential epidermal growth factor receptor inhibitor.

result::

The IC50 of T22306 on H1975 cells was 9.17 μM. In further kinase evaluation, the kinase inhibition of EGFRL858R/T790M was 69.17%. In addition, Time-dependent, Scratch and AO staining assays confirmed the potential of compound T22306 as an EGFR-TKI inhibitor, while Hemolysis assays showed no significant toxicity. Finally, molecular docking revealed the formation of a critical hydrogen bond between compound T22306 and the 5HG7 protein, while the T22306-5HG7 complex was shown in molecular dynamics simulations to have a low binding energy (-117.728 ± 18.688 kJ/mol), thus suggesting that T22306 binds tightly to the target protein 5HG7.

05 Nov 2024·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity

Article

Author: Eck, Michael J. ; Beyett, Tyler S. ; Rana, Jaimin K. ; Schaeffner, Ilse K. ; Zhao, Hanchen ; Jiang, Jie ; Santana, Jhasmer ; Jänne, Pasi A.

Somatic mutations in the epidermal growth factor receptor (EGFR) are a major cause of non–small cell lung cancer. Among these structurally diverse alterations, exon 20 insertions represent a unique subset that rarely respond to EGFR tyrosine kinase inhibitors (TKIs). Therefore, there is a significant need to develop inhibitors that are active against this class of activating mutations. Here, we conducted biochemical analysis of the two most frequent exon 20 insertion variants, V769_D770insASV (insASV) and D770_N771insSVD (insSVD) to better understand their drug sensitivity and resistance. From kinetic studies, we found that EGFR insASV and insSVD are similarly active, but have lower K m, ATP values compared to the L858R variant, which contributes to their lack of sensitivity to 1st-3rd generation EGFR TKIs. Biochemical, structural, and cellular studies of a diverse panel of EGFR inhibitors revealed that the more recently developed compounds BAY-568, TAS6417, and TAK-788 inhibit EGFR insASV and insSVD in a mutant-selective manner, with BAY-568 being the most potent and selective versus wild-type (WT) EGFR. Cocrystal structures with WT EGFR reveal the binding modes of each of these inhibitors and of poziotinib, a potent but not mutantselective inhibitor, and together they define interactions shared by the mutant-selective agents. Collectively, our results show that these exon20 insertion variants are not inherently inhibitor resistant, rather they differ in their drug sensitivity from WT EGFR. However, they are similar to each other, indicating that a single inhibitor should be effective for several of the diverse exon 20 insertion variants.

01 Sep 2024·EUROPEAN JOURNAL OF CANCER

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Article

Author: Wolf, Jürgen ; Abreu, Delvys Rodriguez ; Solomon, Benjamin J ; Ponce-Aix, Santiago ; Ardizzoni, Andrea ; Smith, Nathalie ; Tan, Daniel Sw ; Jary, Aline ; Cui, Xiaoming ; Giovannini, Monica ; Campelo, Maria Rosario Garcia ; Sequist, Lecia V ; Metro, Giulio ; Sprauten, Mette ; Belli, Riccardo ; Yang, James Chih-Hsin ; Glaser, Sabine ; Barlesi, Fabrice ; Zou, Mike ; Soo, Ross A ; Djentuh, Leslie O'Sullivan ; Lee, Dae Ho ; Felip, Enriqueta

PURPOSE:

This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).

METHODS:

In phase 1b, patients with progression on first-/second-generation EGFR-TKIs received escalating doses of capmatinib 200-400 mg bid plus nazartinib 50-150 mg qd. Once the MTD/RP2D was declared, phase 2 commenced with patient enrollment into groups according to mutation status and prior lines of treatment: group 1 (fasted; EGFR-TKI resistant; 1-3 prior lines; EGFR^{L858R/ex19del}; any T790M/MET); group 2 (fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET); group 3 (fasted; treatment-naïve; EGFR^{L858R/ex19del}; T790M-; any MET); group 4 (with food; 0-2 prior lines; EGFR^{L858R/ex19del}; any T790M/MET). Primary endpoints in phase 2 were investigator-assessed overall response rate (ORR) per RECIST v1.1 (groups 1-3), safety, and tolerability of the combination with food (group 4). Efficacy was assessed by T790M and MET status for a subgroup of patients.

RESULTS:

The RP2D was capmatinib 400 mg bid plus nazartinib 100 mg qd. In phase 2 (n = 144), the ORR was 28.8 %, 33.3 %, 61.7 %, and 42.9 % in groups 1 (n = 52), 2 (n = 3), 3 (n = 47), and 4 (n = 42), respectively. In group 1 +phase 1b RP2D, the ORR was 45.8 %, 26.2 %, 37.9 %, and 32.4 % in MET+ (n = 24), MET- (n = 42), T790M+ (n = 29), and T790M- (n = 34) patients. Most common any-grade treatment-related adverse events (≥25 %; n = 144) were peripheral edema (54.9 %), nausea (41.7 %), diarrhea (34.0 %), and maculopapular rash (25.0 %).

CONCLUSION:

Capmatinib plus nazartinib showed antitumor activity in patients with EGFR-TKI-resistant, EGFR-mutated NSCLC. The overall safety profile was acceptable.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov NCT02335944.

News (Medical) associated with Nazartinib

04 Nov 2022

·www.prnewswire.com

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) who have failed to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. This trial is a randomized, double-blind, multi-center Phase III clinical trial, which started patient enrollment in end of January 2022, and it has enrolled 320 participants as of the date of this press release. The primary endpoint of the trial is progression-free survival (PFS) assessed by IRRC. This therapy was granted Breakthrough Therapy Designation by the Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) lately in October 2022. Lung cancer is a malignant tumor with high incidence and high mortality rates worldwide. The incidences of lung cancer around the world and in China have exceeded 2.2 million and 810 thousand respectively in 2020. Non-small cell lung cancer (NSCLC) patients account for 85% of total lung cancer patients, and about 70% of NSCLC patients are diagnosed at advanced stages. In China, nsq-NSCLC accounts for 70% of NSCLC, and about 40%-50% of nsq-NSCLC patients have EGFR mutation. Immunotherapy plus anti-angiogenesis therapy has proved its combination advantages in previous studies worldwide. Lung cancer is one of the mainstream exploration areas of this therapy. AK112 could simultaneously block PD-1 and VEGF targets and has demonstrated favourable safety profile and promising anti-tumor efficacy in ongoing studies conducted by Akeso. AK112 in combination with chemotherapy is expected to provide a novel and effective therapy for the treatment of EGFR-mutated locally advanced or metastatic nsqNSCLC patients who have failed to EGFR-TKI treatment. ABOUT IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) Ivonescimab is a first-in-class and the first to enter phase III clinical trial PD-1/VEGF bi-specific antibody independently developed by Akeso. Engineered with our unique Tetrabody technology, Ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors. PD-1 antibody combined with VEGF blocking agents have shown robust efficacy in various tumor types (including renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma). In view of the co-expression of VEGF and PD-1 in the tumor microenvironment, Ivonescimab, as a single agent to block these two targets, may block these two pathways more effectively and enhance the antitumor activity, as compared to combination therapy. Currently, Akeso is conducting a phase III clinical trial of AK112 monotherapy versus Pembrolizumab monotherapy as the first-line treatment for NSCLC patients with positive PD-L1 expression. In addition, a phase III clinical trial of AK112 plus chemotherapy versus chemotherapy in EGFR mutated advanced non-squamous NSCLC that failed in prior EGFR-TKI therapy is ongoing. AK112 has been investigated in multiple clinical trials for various stages treatment of indications including non-small cell lung cancer and small cell lung cancer.

AntibodyBreakthrough TherapyPhase 3

16 Sep 2022

·www.prnewswire.com

J INTS BIO's Novel Oral 4th Generation EGFR-TKI 'JIN-A02' effective against both cis and trans isomers of C797S mutations - ESMO 2022

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the ESMO 2022, that showed high potency of JIN-A02 against both cis and trans isomers of C797S mutation. This year's edition of the European Society for Medical Oncology Congress (ESMO 2022) was held in Paris, France from 9th to 13th September. Continue Reading Professor Cho, Byoung Chul, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022) Even though EGFR-TKI have improved treatment outcomes of patients with EGFR mutant NSCLC, resistance inevitably emerges with disease progression and often with CNS metastasis. C797S mutation is one of the most common on-target resistance mutation after the use of 3rd generation TKIs such as Osimertinib. 'JIN-A02' is a novel 4th generation EGFR-TKI, which is highly selective and potent against C797S double and triple mutations, with high BBB penetrance and intracranial efficacy. The allelic context in which this C797S mutation is acquired, cis or trans isomers, have significant implications for treatment outcomes. This is especially so when C797S positive tumor are in cis form together with T790M mutation. In such situations, there are no available treatments. J INTS BIO believes that JIN-A02 will be pivotal in the treatment of patients with EGFR mutant NSCLC harboring C797S double or triple mutations, regardless of allelic context. And the company is expecting the Phase I/IIa clinical study for JIN-A02 to start recruitment before the end of this year. About J INTS BIO J INTS BIO is a bio company specialized in developing innovative anti-cancer and orphan drugs to realize the goal of changing lives and improving health for patients around the world. J INTS BIO's teams have prior multi-year experience in multinational pharmaceutical companies and CROs and track records in medical, regulatory affairs, drug discovery and development. About 'JIN-A02' 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC. Although 1st, 2nd, and 3rd Generation EGFR TKIs have been used with some success, recurrence occurs in most patients including 3rd Generation TKIs such as Osimertinib. Currently, there are no approved therapies for patients who developed EGFR C797S mutations due to the use of 3rd Generation EGFR TKIs and with the high propensity of these cancers to metastasize to the brain, there is an urgent need to develop an effective drug with high blood-brain barrier permeability. 'JIN-A02', a novel oral EGFR TKI, which is effective against C797S double and triple mutations and have a high brain penetrance, is therefore expected to become the most promising Best-in-Class 4th-generation EGFR TKI in NSCLC patients with limited or no viable treatment options. SOURCE J INTS BIO

Pre-Clinical Data

25 Aug 2022

·www.prnewswire.com

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces the completion of last patient last visit (LPLV) in its international, multicenter EVEREST phase II/III clinical study of Zorifertinib, a next-generation EGFR-TKI, in first line patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Topline data from this MRCT study are expected around the end of 2022, at which time Alpha Biopharma could submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA). As the international leading principal investigator (PI) of EVEREST study, Professor Yilong Wu, President of the Chinese Thoracic Oncology Group (CTONG), said: "EVEREST study is an international, multicenter, phase II/III randomized clinical study. It is also the only large-scale prospective international multicenter clinical study worldwide for first line EGFRm+ NSCLC patients with CNS metastases to date. It was carried out in 55 study sites located in Chinese mainland, Taiwan, South Korea, and Singapore, with a total enrollment of 492 patients. The clinical and preclinical data of Zorifertinib have shown its high blood-brain barrier (BBB) penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and extra-cranial diseases, and similar safety profile as other EGFR-TKI drugs. If approved, it is expected to provide a valuable choice for treatment of EGFRm+ NSCLC patients with CNS metastases. As the name EVEREST suggests, the study sponsor and investigators are dedicated to solving important unmet clinical needs." Professor Jie Wang, Director of Oncology Department of Cancer Hospital Chinese Academy of Medical Sciences, and co-leading PI of EVEREST study, said: "Lung cancer with CNS metastases has always been a challenging problem and leading cause of death for these patients. Zorifertinib is a next-generation, high-potent EGFR-TKI drug targeting sensitive mutations of exon 19 deletion or L858R in EGFR gene with good exposure in CNS lesions. It is not a substrate of efflux transporter P-gp and BCRP, thus not only capable of fully passing through BBB, but also maintaining high drug exposure in the brain tissue and cerebrospinal fluid. It was intentionally designed to optimize its physicochemical and biochemical properties meet the requirements of CNS penetration, which has been proven to be the case in this and prior clinical studies. We look forward to the finale data readout and if positive, a direly needed treatment for these patients." Dr. Ruilin Song, Executive President of China Pharmaceutical Innovation and Research Development Association, said: "In the past three years, the COVID-19 pandemic in some regions of China has brought great challenges to innovative biotech companies. Many clinical study sites faced challenges in terms of regional lockdown, logistics, and clinical operations. However, the clinical development team at Alpha Biopharma and investigators worked together to overcome difficulties to achieve the key milestones of the EVEREST study. They diligently communicated with study sites to come up with solutions, paid full attention to the safety of the subjects and the quality of the trial data while ensuring the uninterrupted treatment of the subjects. In recognizing this pivotal milestone of EVEREST study completion, we would like to express sincere respect for the efforts of all relevant personnel involved in the study and wish Zorifertinib a smooth NDA submission. We are a step closer to bringing new hope to patients with CNS metastases of EGFRm+ NSCLC." About Zorifertinib Zorifertinib is a potent, oral, reversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TKI) activating mutation (L858R and Exon19Del). EGFR is widely expressed in human epidermal cells and stromal cells and is highly expressed in a variety of human malignancies, such as NSCLC. EGFR gene mutation will cause excessive epidermal growth factor receptors on the cell membrane surface, accelerate the abnormal growth and division of cells, and eventually lead to tumorigenesis. CNS metastases is common in EGFRm+ NSCLC patients and accompanied with poor prognosis of earlier disease progression, shorter survival, and lower quality of life. The BBB significantly increases the difficulty of drug penetration into CNS, which allows the CNS to be a refuge for lung cancer cells. Zorifertinib is a new-generation EGFR-TKI specifically designed to fully penetrate the BBB to target brain metastases. Zorifertinib is in late-stage clinical studies and has global intellectual property protection. About Alpha Biopharma Alpha Biopharma is a late-stage biopharmaceutical company focused on developing potential new therapies for cancer's unmet medical need. Founded in 2017, the Company has advanced its EGFRm+ targeted small molecule drug Zorifertinib to its Phase II/III trial (EVEREST) to treat NSCLC patients with brain metastases. In addition, Alpha Biopharma has initiated an IIT clinical study of an NK cell therapy targeting AML and is developing CAR-T cell therapy that it licensed from Wugen Inc. for the Greater China region. Alpha BioPharma's experienced team, leading clinicians, and collaborators integrate their oncology expertise to find innovative solutions to transform the lives of cancer patients. SOURCE ALPHA BIOPHARMA

Innovative DrugCell TherapySmall molecular drug

100 Deals associated with Nazartinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11430	-	-	DB16250

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	-	Novartis Pharmaceuticals Corp.	24 Jul 2018
metastatic non-small cell lung cancer	Phase 3	-	Novartis Pharmaceuticals Corp.	24 Jul 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 2	Canada	Novartis Pharmaceuticals Corp.	13 Jan 2015
EGFR-mutated non-small Cell Lung Cancer	Phase 2	South Korea	Novartis Pharmaceuticals Corp.	13 Jan 2015
Advanced Lung Non-Small Cell Carcinoma	Phase 2	United States	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Japan	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Canada	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Germany	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Netherlands	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Singapore	Novartis Pharmaceuticals Corp.	06 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03292133 (CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	11	EGF816+Gefitinib	rxewcywphj = byyrdaxzwv chmednsnqw (yskqrzvgqf, enfrrwsglh - zedeqrbjpm) View more	-	10 Jun 2025
NCT03516214 (EATON, ASCO2025)	Phase 1	Bronchial Neoplasms \| Non-Small Cell Lung Cancer EGFRmut \| EGFR p.T790M-positive	19	Nazartinib 100 mg	rprzfrvowk(seitspjohr) = wgjdlnewze hetqedgdxz (tpixxvuecu, 1.6 - 30.2) View more	Negative	30 May 2025
NCT02335944 (Pubmed) Manual	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation ... View more	144	Capmatinib Nazartinib plus Nazartinib 100 mg qd	bzrujrasqv(mlfcuwqawt) = niewoxsiqv nkmpsjfenv (xcfqiuakij )	Positive	01 Sep 2024
NCT02335944 (Pubmed) Manual	Phase 1/2		144	Capmatinib+Nazartinib (fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET)	bzrujrasqv(mlfcuwqawt) = tmevmgbeih nkmpsjfenv (xcfqiuakij )	Positive	01 Sep 2024
NCT02108964 (Pubmed) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	45	Nazartinib	hxbykvxgne(zjprrdestu) = erzvpggsqq dovpbxxrow (zlbcidjgjv, 53 - 82) View more	Positive	07 Jul 2022
NCT02108964 (Pubmed) Manual	Phase 2		45	Nazartinib (brain metastases)	hxbykvxgne(zjprrdestu) = sgunfqtmcu dovpbxxrow (zlbcidjgjv, 41 - 87) View more	Positive	07 Jul 2022
NCT02323126 (GEOMETRY mono-1, CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	64	EGF816+Nivolumab (Nivolumab and EGF816)	npzbdgbfvo = mgoxeiynih igtyixcehj (pnmgscvybv, hfilmwslqq - fzzztmolge) View more	-	15 Jun 2021
NCT02323126 (GEOMETRY mono-1, CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	64	Nivolumab+INC280 (Nivolumab and INC280, High cMet)	npzbdgbfvo = feuizaqocj igtyixcehj (pnmgscvybv, qiygsqhfga - jxiajjvnky) View more	-	15 Jun 2021
NCT02335944 (ESMO2020) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer MET Positive	115	capmatinib+nazartinib (Group 1)	sfdnvhfwyi(bneerdopxu) = pilzxpaqeh qgasisghnh (vazjcrbbhl, 17.1 - 43.1) View more	Positive	17 Sep 2020
NCT02335944 (ESMO2020) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer MET Positive	115	capmatinib+nazartinib (Group 1 + Ph 1b RP2D + MET+)	sfdnvhfwyi(bneerdopxu) = ihgmtqsjmn qgasisghnh (vazjcrbbhl, 23.2 - 65.5) View more	Positive	17 Sep 2020
NCT02108964 (Pubmed) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	180	nazartinib	cwlmtllygp(nfqnlpfuzl) = vtdnaozsrc jipebvpezm (ghewfujvem ) View more	Positive	01 Jun 2020
NCT02108964 (ESMO2018)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	45	Nazartinib 150 mg QD	hairfgmvtq(kfanlmbmsr) = vnizwepkox lgrqnsgpvy (hlvslspcpn, 49% - 78%) View more	Positive	19 Oct 2018
NCT02108964 (ASCO2018)	Phase 2	Solid tumor \| Advanced Lung Non-Small Cell Carcinoma	40	Nazartinib 150 mg QD	obmzshexwx(mtinigjqeu) = Gr 3 AEs occurred in 10/40 (25%) pts, most commonly (≥5%) maculopapular rash in 4/40 (10%) pts and hypokalemia in 2/40 (5%) pts; there were no Gr 4 AEs fgiprnyrgv (ucrvjrvgtp ) View more	Positive	01 Jun 2018
NCT02108964 (ASCO2017)	Phase 1/2	Non-Small Cell Lung Cancer	9	EGF816	nsezzeepxo(uzdhrqkhat) = ltceeoqbdq wpxpwcwvmo (klzbtdarcb ) View more	-	30 May 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis